Similarly, we observed the increase in GPx activity when MDS patients were divided in relation to the score mutational, observing an increase in GPx activity in patients with a high number of total mutations (>3 total mutations) (p < 0.01) (Figure 5B) and with an increase in LPO values (p < 0.05) with respect to those with low mutational score (≤2 total mutations). This evidence concerns the gene LPO and myelodysplastic syndrome.